An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress tGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor tGLI1.
Saved in:
| Title: | An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress tGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor tGLI1. |
|---|---|
| Authors: | Doheny, Daniel1 (AUTHOR), Manore, Sara1 (AUTHOR), Sirkisoon, Sherona R.1 (AUTHOR), Zhu, Dongqin1 (AUTHOR), Aguayo, Noah R.1 (AUTHOR), Harrison, Alexandria1 (AUTHOR), Najjar, Mariana1 (AUTHOR), Anguelov, Marlyn1 (AUTHOR), Cox, Anderson O'Brien2 (AUTHOR), Furdui, Cristina M.2,3,4 (AUTHOR), Watabe, Kounosuke1,4 (AUTHOR), Hollis, Thomas4,5 (AUTHOR), Thomas, Alexandra4,6 (AUTHOR), Strowd, Roy4,7 (AUTHOR), Lo, Hui-Wen1,4 (AUTHOR) hlo@wakehealth.edu |
| Source: | Cancers. Sep2022, Vol. 14 Issue 17, p4256. 21p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20726694 |
|---|---|
| DOI: | 10.3390/cancers14174256 |
